Dihydropyridine (DHP) calcium channel blockers are a class of medications used to treat hypertension and angina pectoris. They work by blocking L-type calcium channels in vascular smooth muscle, leading to vasodilation and a reduction in blood pressure.
How do DHP calcium channel blockers work?
These drugs specifically target the voltage-gated L-type calcium channels found in the cell membranes of vascular smooth muscle. By inhibiting the influx of calcium ions into these cells, DHPs prevent the contraction of smooth muscle in blood vessel walls. This relaxation, or vasodilation, lowers peripheral vascular resistance and consequently reduces blood pressure. In the context of angina, by dilating coronary arteries, they can improve blood flow to the heart muscle.
What are the main types of DHP calcium channel blockers?
The DHP class includes several medications, often categorized by their duration of action. Shorter-acting agents like nifedipine can be used for rapid blood pressure control but may carry a risk of reflex tachycardia. Longer-acting agents, such as amlodipine, felodipine, and nicardipine, are generally preferred for chronic management of hypertension due to their sustained effects and reduced risk of acute hemodynamic changes.
How do DHP calcium channel blockers differ from non-DHP calcium channel blockers?
Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, also target calcium channels but have a more pronounced effect on cardiac muscle in addition to vascular smooth muscle. While DHPs primarily cause vasodilation, non-DHPs can also slow heart rate and reduce the heart's contractility. This distinction influences their therapeutic uses and potential side effect profiles.
When does patent exclusivity expire for DHP calcium channel blockers?
Patent exclusivity for many of the earlier DHP calcium channel blockers has already expired, leading to the availability of generic versions. For instance, original patents for amlodipine expired years ago, making it widely available as a generic medication. DrugPatentWatch.com provides detailed information on patent expiry dates for numerous pharmaceuticals, including DHP calcium channel blockers.
What are the common side effects of DHP calcium channel blockers?
The most common side effects associated with DHP calcium channel blockers are related to their vasodilatory effects. These can include peripheral edema (swelling in the ankles and feet), headache, flushing, and dizziness. Gingival hyperplasia, an overgrowth of gum tissue, is another potential side effect, though less common.
Who manufactures DHP calcium channel blockers?
Many pharmaceutical companies manufacture DHP calcium channel blockers, particularly generic versions. Major generic drug manufacturers as well as innovator companies produce these medications. The specific manufacturer can vary depending on the country and the availability of branded versus generic formulations.